Notice: This company has been marked as potentially delisted and may not be actively trading. Travere Therapeutics (RTRX) News Today Add Compare Share Share Headlines Stock AnalysisCompetitorsHeadlinesTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Kidney Disease Leader Travere Therapeutics Pulls Back To Key LevelNovember 20 at 8:33 AM | msn.comTravere Therapeutics 7.81M share Spot Secondary priced at $16.00November 8, 2024 | markets.businessinsider.comTravere Therapeutics announces common stock offering, no amount givenNovember 7, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from TD CowenNovember 6, 2024 | markets.businessinsider.comTravere Therapeutics: Strong Growth and Strategic Advancements Drive Buy RatingNovember 2, 2024 | markets.businessinsider.comTravere Therapeutics, Inc. (NASDAQ:TVTX) Q3 2024 Earnings Call TranscriptNovember 1, 2024 | msn.comTravere Therapeutics price target raised to $27 from $23 at ScotiabankNovember 1, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Buy from Bank of America SecuritiesNovember 1, 2024 | markets.businessinsider.comPositive FDA Prospects for Travere Therapeutics Boosts Buy RatingOctober 28, 2024 | markets.businessinsider.comEvercore ISI Sticks to Its Buy Rating for Travere Therapeutics (TVTX)October 28, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Receives a Hold from Stifel NicolausOctober 28, 2024 | markets.businessinsider.comTravere presents data reinforcing clinical benefit of FILSPARI in IgANOctober 27, 2024 | markets.businessinsider.comTravere Therapeutics Highlights Clinical Benefits Of FILSPARI For IgA Nephropathy And FSGSOctober 26, 2024 | markets.businessinsider.comJim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'October 24, 2024 | benzinga.comTravere Therapeutics Secures Swiss Authorization For FILSPARI To Treat IgA NephropathyOctober 17, 2024 | markets.businessinsider.comScotiabank Initiates Coverage of Travere Therapeutics (TVTX) with Sector Outperform RecommendationOctober 16, 2024 | msn.comTravere Therapeutics Hits 15-Month High On A Promising FDA 'Pivot' In Kidney DiseaseOctober 10, 2024 | msn.comStrong Buy Rating for Travere Therapeutics Backed by Filspari’s Market Potential and Full FDA ApprovalOctober 3, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Amid Proactive HARMONY Study Management and Strong Financial StanceSeptember 27, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Following Filspari’s Expanded FDA Approval and Positive Market OutlookSeptember 10, 2024 | markets.businessinsider.comTravere Therapeutics (TVTX) Gets a Hold from Wells FargoSeptember 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Travere Therapeutics Amid Positive KDIGO Guideline Developments and Filspari’s Market PotentialSeptember 4, 2024 | markets.businessinsider.comPiper Sandler Remains a Hold on Travere Therapeutics (TVTX)August 28, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Siegfried Holding AG (OtherSGFEF) and Travere Therapeutics (TVTX)August 5, 2024 | markets.businessinsider.comBuy Rating on Travere Therapeutics: Robust Filspari Sales and Strong Market Outlook Justify Outperform StatusAugust 5, 2024 | markets.businessinsider.comOptimistic Outlook for Travere Therapeutics Amidst Solid Performance and Favorable Regulatory ProspectsAugust 4, 2024 | markets.businessinsider.comTravere Therapeutics Poised for Continued Growth: A Buy Rating Based on Strong Financials and Market PotentialAugust 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Assertio Therapeutics (ASRT), Longboard Pharmaceuticals (LBPH) and Travere Therapeutics (TVTX)May 7, 2024 | markets.businessinsider.comExpert Outlook: Travere Therapeutics Through The Eyes Of 6 AnalystsMay 7, 2024 | markets.businessinsider.comCritical Insights From Travere Therapeutics Analyst Ratings: What You Need To KnowApril 17, 2024 | markets.businessinsider.comTravere Therapeutics price target lowered by $3 at H.C. Wainwright, here's whyFebruary 23, 2024 | realmoney.thestreet.comTravere Therapeutics gains as EU backs kidney disease therapyFebruary 23, 2024 | msn.comNew Debt & Financing Risk for Travere Therapeutics, Inc. – What’s the Latest?February 21, 2024 | msn.comTravere Therapeutics price target raised by $4 at Citi, here's whyFebruary 17, 2024 | realmoney.thestreet.comTravere Therapeutics: Hold Rating Amidst Filspari’s Steady Performance and Emerging Market CompetitionFebruary 16, 2024 | markets.businessinsider.comEarnings Preview For Travere TherapeuticsFebruary 14, 2024 | benzinga.comTravere Therapeutics: A Strong Buy on Filspari’s Outperformance and Promising Market ProspectsJanuary 11, 2024 | markets.businessinsider.comOptimistic Outlook for Travere Therapeutics Amid FDA Developments and Strategic ReorganizationDecember 7, 2023 | markets.businessinsider.comTravere (TVTX) Up on Latest Portfolio Updates & ReorganizationDecember 6, 2023 | msn.comBuy Rating for Travere Therapeutics: Optimism Fueled by Regulatory Prospects and Strategic ReorganizationDecember 5, 2023 | markets.businessinsider.comTravere Therapeutics upgraded to Buy from Neutral at CitiDecember 5, 2023 | realmoney.thestreet.comTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsDecember 4, 2023 | marketwatch.comTravere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 21, 2023 | benzinga.comPromising Sales Performance and Growth Prospects Solidify Buy Rating for Travere TherapeuticsNovember 8, 2023 | markets.businessinsider.comPreview: Travere Therapeutics's EarningsNovember 6, 2023 | benzinga.comTravere Therapeutics Inc Ordinary Shares TVTXOctober 31, 2023 | morningstar.comWedbush Reiterates Travere Therapeutics (TVTX) Outperform RecommendationSeptember 30, 2023 | msn.comWhy Former Highflier Travere Therapeutics Just Crashed 41% To A Decade-LowSeptember 22, 2023 | msn.comWhy Shares of Travere Therapeutics Are Slumping ThursdaySeptember 21, 2023 | msn.comBack To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, ChallengesSeptember 21, 2023 | markets.businessinsider.com Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address 📉 Warning: Market Crash Predicted - Secure Your Savings (Ad)The last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%. Take these 4 steps to protect your retirement here >>> RTRX Media Mentions By Week RTRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RTRX News Sentiment▼0.000.48▲Average Medical News Sentiment RTRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RTRX Articles This Week▼10▲RTRX Articles Average Week Get Travere Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Perrigo News Rhythm Pharmaceuticals News Apellis Pharmaceuticals News MoonLake Immunotherapeutics News PTC Therapeutics News Agios Pharmaceuticals News HUTCHMED News Merus News Xenon Pharmaceuticals News Edgewise Therapeutics News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RTRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Travere Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Travere Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
